@cdoyle
" The ongoing Phase III APPLAUSE-IgAN study is evaluating the efficacy and safety of twice-daily oral Fabhalta (200 mg) versus placebo in adult IgAN patients on a stable dose of maximally-tolerated renin-angiotensin system (RAS) inhibitor therapy with or without a stable dose of SGLT2i."
"Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a clinically meaningful reduction of 38% vs. placebo (p<0.0001)." [no idea where you get 35% from- the placebo adjusted is reported as 38%, it's not 44-9 because of how the means are calculated statistically I believe, do you understand what placebo-adjusted is??]
https://www.novartis.com/us-en/news/media-releases/novartis-receives-fda-accelerated-approval-fabhalta-iptacopan-first-and-only-complement-inhibitor-reduction-proteinuria-primary-iga-nephropathy-igan
Please learn to read, and stop embarrassing yourself!!!!
- Forums
- ASX - By Stock
- DXB
- Banter and general comments
Banter and general comments, page-40
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
(20min delay)
|
|||||
Last
45.0¢ |
Change
-0.040(8.16%) |
Mkt cap ! $250.7M |
Open | High | Low | Value | Volume |
48.5¢ | 48.5¢ | 44.8¢ | $1.098M | 2.375M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 337999 | 45.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
46.0¢ | 17466 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 337999 | 0.450 |
4 | 121348 | 0.445 |
1 | 20000 | 0.440 |
1 | 2873 | 0.435 |
3 | 20734 | 0.430 |
Price($) | Vol. | No. |
---|---|---|
0.470 | 88538 | 4 |
0.475 | 18000 | 2 |
0.480 | 44694 | 2 |
0.490 | 112222 | 3 |
0.495 | 111559 | 4 |
Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |